Trevi Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TREVI THERAPEUTICS, INC. | ||
| Date: March 17, 2026 | By: | /s/ Jennifer L. Good |
|---|---|---|
| Jennifer L. Good | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Jennifer L. Good | President and Chief Executive Officer, Director | March 17, 2026 |
| Jennifer L. Good | (Principal Executive Officer) | |
| /s/ David C. Hastings | Chief Financial Officer | March 17, 2026 |
| David C. Hastings | (Principal Financial Officer) | |
| /s/ Christopher Galletta | Controller | March 17, 2026 |
| Christopher Galletta | (Principal Accounting Officer) | |
| /s/ David Meeker, M.D. | Chairman of the Board | March 17, 2026 |
| David Meeker, M.D. | ||
| /s/ Dominick Colangelo | Director | March 17, 2026 |
| Dominick Colangelo | ||
| /s/ Michael Heffernan | Director | March 17, 2026 |
| Michael Heffernan | ||
| /s/ Edward Mathers | Director | March 17, 2026 |
| Edward Mathers | ||
| /s/ Anne VanLent | Director | March 17, 2026 |
| Anne VanLent | ||
Index to Consolidated Financial Statements
Years Ended December 31, 2025 and 2024
Contents
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Consolidated Financial Statements | |
| Consolidated Balance Sheets | F-4 |
| Consolidated Statements of Comprehensive Loss | F-5 |
| Consolidated Statements of Stockholders’ Equity | F-6 |
| Consolidated Statements of Cash Flows | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.